[go: up one dir, main page]

KR900701801A - 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 - Google Patents

2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Info

Publication number
KR900701801A
KR900701801A KR1019900700977A KR900700977A KR900701801A KR 900701801 A KR900701801 A KR 900701801A KR 1019900700977 A KR1019900700977 A KR 1019900700977A KR 900700977 A KR900700977 A KR 900700977A KR 900701801 A KR900701801 A KR 900701801A
Authority
KR
South Korea
Prior art keywords
compound
dipyrrole
methylbenzo
carbonyl
chloromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900700977A
Other languages
English (en)
Other versions
KR0137959B1 (ko
Inventor
씨. 켈리 로보트
에이. 아리스토프 폴
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR900701801A publication Critical patent/KR900701801A/ko
Application granted granted Critical
Publication of KR0137959B1 publication Critical patent/KR0137959B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Error Detection And Correction (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid State Image Pick-Up Elements (AREA)
  • Artificial Filaments (AREA)
  • Amplifiers (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Television Systems (AREA)
  • Television Receiver Circuits (AREA)
  • Stereophonic System (AREA)

Abstract

내용 없음

Description

2개의 CP1 소단위를 갖는 신규한 CC-1O65 유사화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(I)의 화합물
    CPI1-R5-T-R'5-CPL (I)
    상기식에서, CP11및 CP12는 같거나 다르며, 하기 일반식(A) 또는 (B)로 부터 선택되고;
    (여기에서, W는 C1-C5알킬, 페닐 또는 수소로부터 선택되고: X는 아지도, 할로겐원자, 시아네이트, 티오시아네이트, 이소시아네이트, 티오이소시아네이트, 인산 디에스테르(-PO(OR)2), 포스포닐(-O-PO2R), 티오포스포닐(-0-PSOR), 설피닐(-0-SOR) 또는 설포닐(-0-SO2R)로 부터 선택되고: Y는 수소, -C(O)R, -C(S)R, -C(O)OR1, -S(O)2R4, -C(O)NR2R3, -C(S)NR2R3- 또는 -C(O)NHS02R4로 부터 선택되고: Z는 C1-C5알킬, 페닐 또는 수소로 이루어진 그룹으로 부터 선택되고: R은 C1-C20알킬: C2-C5알케닐: C2-C5알키닐: 1,2 또는 3개의 C1-C4알킬, C1-C3알콕시, 할로, C1-C3알킬티오, 르리폴무오로메틸, C2-C6디알킬아미노, 또는 니트로로 임의로 치환된 페닐: 1 또는 2개의 C1-C4알킬, C1-C3알콕시, 할로, 니트로로 임의로 치환된 페닐; 1 또는 2개의 C1-C4알킬, C1-C3알콕시, 할로 트리플루오로에틸, C2-C5디알킬아미노, C1-C3알키티오 또는 니트로로 임의로 치환된 나프틸이다); R5및 R'2는 같거나 다르며, 직접 결합하거나 하기 그룹중에서 선택된 카보닐 아실 그룹이고:
    (여기에서, X1은 H, CH3, OH, OCH3, NO2, NH2, (NHNHAc)NHNHC(O)CH|3, (NHBz)NHC(O)C6H5, 또는 할로겐이다):
    (여기에서 X2는 H, OH 또는 OCH3이다):
    (여기에서, R8은 H, CH3또는 C2H5이다):
    (여기에서 R'는 H 또는 CH3S-이다):
    (여기에서 X8은 -O-, -S-, NH이고: X9는 -CH= 또는 -N= 이다) :
    (여기에서 X9및 X8은 상기 정의한 바와 같으며: Y1은 H, 할로, C1-C4-알킬, C1-C3-알콕시, C2-C6-디알킬 아미노, 니트로, 아미노-카보닐알킬(C|1-C10) 하이드록시, 아미노(-NH2), -NHC0NH2, -NHAc(NHC0CH3) 또는 -NHBz(NHC(O)-C6H|5이다);
    (여기에서 X8및 Y1은 상기 정의한 바와 같다);
    (여기에서 X10은 -CH= 또는 -N= 이다);
    (여기에서 X10은 상기 정의한 바와 같다);
    (여기에서 R8은 상기 정의한 바와 같다);
    (여기에서 Y1, Y2및 X8은 상기 정의한 바와 같다);
    (여기에서 Y1, Y2, X8및 X9는 상기 정의한 바와 같다);
    (여기에서 X10은 -CH= 또는 -N= 이며, Y1및 Y2는 상기 정의한 바와 같다);
    (여기에서 Y1및 Y2는 상기 정의한 바와 같다);
    T는 (a)아미노카보닐 (-NHC(O)-): (b)카보닐아미노(-C(O)NH-): (c)카보닐옥시(-C(O)O-): (d) 옥시카보닐(-0C(O)-); (e) 일반식 -NR13-T'-NR14-의 아미노-연결-아미노 〔여기에서 R13및 R14는 같거나 다르며, 수소 또는 C1-C8알킬이거나, 또는 함께 결합하여 -(CH2)n-(이때 n은 2 또는 3이다)이고: T'는 카보닐(-C(O)-), 디카보닐(-C(O)C(O)-), (-CO)(CH2)nC(O)-) (이때 n은1 내지 5이다), (-C(O)PhC(O)-) (이때 Ph는 1,3- 또는 1,4-페닐렌이다) 또는 일반식 -C(O)-het-C (O)-(이때 -het-는 하기 정의한 바와같다)의 그룹으로 이루어진 군으로부터 선택된다〕: 또는 (f) R5및 R'5가 둘다 직접 결합하는 경우의 -C(O)-het-C(O)-〔여기에서 -het-는 산소, 질소 또는 황으로 이루어진 그룹으로 부터 선택된 1,2 또는 3개의 헤테로원자를 함유하는 5원 내지 12원의 융합된 일환-, 이환, 또는 삼환 헤테로 아릴(이때 헤테로 아릴은 1 또는 2개의 C1-C4알킬, C1-C3알콕시, 할로, C1-C|3알킬티오, 트리플루오로메틸, C2-C6디알킬아미노, 또는 니트로로 임의로 치환된다)이다〕로 부터 선택된 연결 결합이다.
  2. 제1항에 있어서, E가 메틸인 화합물.
  3. 제1항에 있어서, X가 할로겐인 화합물.
  4. 제1항에 있어서, Y가 수소, 또는 -C0R(여기에서 R은 C1-C10알킬로부터 선택된다)로 이루어진 그룹으로부터 선택되는 화합물.
  5. 제1항에 있어서, Z가 수소인 화합물.
  6. 제1항에 있어서, T가 아미드(아미노카보닐), 카보닐아미노(-C(O)NH-), 또는 일반식 -NR13-T'-NR14-〔여기에서, R13및 R14는 수소이고, T'는 카보닐(-C(O)-) 또는 일반식 -C(O)-het-C(O)-(이때 -het-는 제1항에서 정의한 바와같다)의 그룹으로부터 선택된다〕의 아미노-연결-아미노로 이루어진 그룹으로 부터 선택된는 화합물.
  7. 제1항에 있어서, T가 일반식 -NR13-T'-NR14-〔여기에서, R13및 R14는 수소이고, T'는 카보닐(-C(O)-) 또는 일반식 -C(O)-het-C (O)-(이때 -het-는 피롤-2,5-디일, 푸르-2,5-디일, 인돌-2,5-디일, 벤조푸란-2,5-디일 또는 3,6-디하이드로벤조 〔1,2-b :4-3-b'〕디피롤-2,7-디일로부터 선택된 헤테로아릴이다)의 그룹으로 부터 선택된다〕의 아미노-연결-아미노로 이루어진 그룹으로 선택되는 화합물.
  8. 제1항에 있어서, R5및 R'5가 2-카보닐인돌-5-일, 2-카보닐-6-하이드록시-7-메톡시인돌-5-일, 2-카보닐-1,2,3,6-테드라하이드로벤조 〔1,2b :4,3-b'〕디피롤-7-일, 2-카보닐-4-하이드록시-5-메톡시-1,2,3,6-테드라하이드로벤조 〔1,2-b :4,3-b'〕디피롤-7-일로 이루어진 그룹으로 부터 선택되는 화합물.
  9. 제1항에 있어서, CPI1및 CP12가 같거나 다르며, 바람직하게는 1-(클로로 메틸)-1,6-디하이드로-8-메틸-5-하이드록시-벤조 〔1,2-b :4,3-b'〕디피롤-3(2M-일 및 4,5,8,8a-테트라하이드로-7-메틸-4-옥소사이클로프로판〔C〕피롤로(3,2-e)인돌-2(1H)-일인 화합물.
  10. 제1항에 있어서, 하기 화합물들로 이루어진 그룹으로부터 선택되는 화합물:
    〔S-(R*,R*)〕 -6.6'-〔카보닐비스(이미노-1H-인돌-5,2-디카보닐)〕 비스 〔8-(클로로메틸)-3,6,7,8-테트라하이드로-1-메틸벤조 〔1,2,-b : 4,3-b'〕디피롤-4-올 (화합물 1):
    〔7bR-〔2(7'(R*, 8',aS*), 7bR*, 8aS*〕〕 -2,2'-〔카보닐비스(이미노-1H-인돌-5,2-디카보닐)〕 비스〔1,2,8,8a-테트라하이드로-7-메틸-사이클로프로판(C)피롤로 〔3,2-e〕 인돌-4(5H)-은 (화합물 2):
    (R*,S*)-N,N'-비스 〔2-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b :4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -1H-인돌-5-일〕 에탄디아미드 (화합물 3):
    〔S-(R*,R*〕-6,6'-(1H-피롤-2,5-디일디카보닐) 비스 〔8-(클로로메틸)-3,6,7,8-테트라하이드로-1-메틸벤조 〔1,2-b:4,3-b'〕디피롤-4-올 (화합물 4):
    〔S-(R*,R*)〕-6.6'-(2,5-푸란디일디카보닐) 비스 〔8-(클로로메틸)-3,6,7,8-테트라하이드로-1-메틸벤조 〔1,2-b : 4,3-b'〕디피롤-4을 (화합물 5):
    (R*,S*)-N,N'-비스 〔2-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b :4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -1H-인돌-5-일〕 -2,5-푸란디카복스아미드 (화합물 6):
    〔S-(R*,S*)-N,N'-비스 〔2-〔〔1-(클로로에틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b :4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -1H-인돌-5-일〕 -1H-피롤-2,5-디카복스아미드 (화합물 7);
    〔R-(R*,S*)〕 -N,N'-비스 〔2-〔〔1-(클로로메틸)-1,6-피하이드로-5-하이드록시-8-메틸벤조 〔1,2-b:4.3-b'〕디피롤-3(2H)-일〕 카보닐-lH-인돌-5-일〕 프로판디아미드 (화합물 8):
    〔S-(R*,R*)〕-〔카보닐비스(이미노-1H-인돌-5,2-디일카보닐〕 -비스 〔-8-(클로로메틸)-3,6,7,8-테트라하이드로-2-메틸벤조 〔1,2-b : 4,3-b'〕디피를-1-올 디아세테이트 (화합물 9):
    〔S-(R*,R*)〕-6,6'-(lH-인돌-2,5-디일디카보닐)비스 〔8-(클로로메틸)-3,6,7,8-테트라하이드로-1-메틸벤조 〔1,2. -b:4,3-b'〕디피롤-4-올 (화합물 1O):
    〔S-(R*,R*)-N,N'-비스 〔2-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -1H-인돌-5-일〕 -1H-인돌-2,5-디카복스아미드 (화합물 11);
    〔S-(R*,R*)-2-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b :4,3-b'〕디피롤-3(2H)-일〕카보닐〕-N-〔3-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록서-8-메틸벤조〔1,Z-b : 4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -1H-인돌-6-일〕-1H-인돌-5-카복스아미드 (화합물 12) :
    〔S-(R*,R*)-2-〔〔1-(클로로메틸)-1, 6-디하이드로-5-하이드록시-8-메틸벤조 〔1,2-b : 4,3-b'〕디피롤-3(2H)-일〕카보닐〕 -N-〔3-〔〔1-(클로로메틸)-1,6-디하이드로-5-하이드록시-8-메틸벤조〔1,2-b : 4,3-b'〕디피물-3(2H)-일〕카보닐〕 -1H-인돌-6-일〕 -1H-인돌-5-카복스아미드 (화합물 13) :
    〔S-(R*,R*)-카보닐비스 〔이미노-1H-인돌-5,2-디일카보닐 〔1-(클로로메틸)-1,6-디하이드로-8-메틸벤조 〔1,2-b:4,3-b'〕디피롤-3,5(2H)-디일〕〕 에스테르, 2,2-디에틸프로 파노산 (화합물 14):
    〔S-(R*,R*)-카보닐비스 〔이미노-1H-인돌-5,2-디일카보닐 〔1-(클로로메틸)-1,6-디하이드로-8-메틸벤조 〔1,2-b :4,3-b'〕디피롤-3,5(2H)-디일〕〕 에스테르, 2,2-디메틸프로 파노산 (화합물 15):
    〔S-(R*,R*)〕-6,6'-〔카보닐비스〔(7,8-디하이드로벤조 〔1,2-b :4,3-b'〕디피롤-6,2(3H)-디일)카보닐〕〕 비스 〔8-(클로로 메틸)-3,6,7,8-테드라하이드로-1-메틸벤조 〔1,2,-b :4-3-b'〕디피롤-4-올 (화합물 16).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700977A 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 Expired - Fee Related KR0137959B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24335088A 1988-09-12 1988-09-12
US7/243,350 1988-09-12
US07/243,350 1988-09-12
PCT/US1989/003329 WO1990002746A1 (en) 1988-09-12 1989-08-07 Novel cc-1065 analogs having two cpi subunits

Publications (2)

Publication Number Publication Date
KR900701801A true KR900701801A (ko) 1990-12-04
KR0137959B1 KR0137959B1 (ko) 1998-05-15

Family

ID=22918400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700977A Expired - Fee Related KR0137959B1 (ko) 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Country Status (14)

Country Link
US (1) US5541339A (ko)
JP (1) JP3380237B2 (ko)
KR (1) KR0137959B1 (ko)
AT (1) ATE198335T1 (ko)
AU (1) AU632288B2 (ko)
CA (1) CA1340215C (ko)
DE (1) DE68929275T2 (ko)
DK (1) DK175458B1 (ko)
FI (1) FI103668B1 (ko)
GR (1) GR3035589T3 (ko)
LV (1) LV12806B (ko)
NO (1) NO303498B1 (ko)
TW (1) TW217383B (ko)
WO (1) WO1990002746A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
MXPA04004301A (es) 2001-11-09 2004-08-11 Boehringer Ingelheim Pharma Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
AU2003257094A1 (en) * 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US20050215614A1 (en) * 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
MX2008002364A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en tiofeno y en furano de alta afinidad.
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
US8889868B2 (en) 2008-11-03 2014-11-18 Syntarga Bv CC-1065 analogs and their conjugates
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
WO2014066400A2 (en) 2012-10-22 2014-05-01 Arnold Glazier Methods for the effective treatment of metastatic cancer
DE102013012622A1 (de) * 2013-07-30 2015-02-05 Clariant lnternational Ltd Neue sterisch gehinderte cyclische Amine
US10266606B2 (en) 2014-01-10 2019-04-23 Synthon Biopharmaceuticals B.V. Method for purifying Cys-linked antibody-drug conjugates
ES2722103T3 (es) * 2014-01-27 2019-08-07 Pfizer Agentes citotóxicos bifuncionales
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
DE102015000124A1 (de) * 2015-01-07 2016-07-07 Clariant International Ltd. Verfahren zur Stabilisierung von Polyamiden
US10870706B2 (en) * 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4301248A (en) * 1979-12-21 1981-11-17 Bristol-Myers Company Fermentation process for making rachelmycin
US4413132A (en) * 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
GB8528848D0 (en) * 1985-11-22 1985-12-24 Davy Mckee Poole Rolling mills
AU617304B2 (en) * 1986-12-19 1991-11-28 Pharmacia & Upjohn Company Novel cc-1065 analogs

Also Published As

Publication number Publication date
LV12806A (en) 2002-03-20
CA1340215C (en) 1998-12-15
DE68929275D1 (de) 2001-02-01
TW217383B (ko) 1993-12-11
LV12806B (lv) 2002-05-20
NO910958D0 (no) 1991-03-11
WO1990002746A1 (en) 1990-03-22
FI911193A0 (fi) 1991-03-11
DK41791A (da) 1991-03-08
JP3380237B2 (ja) 2003-02-24
NO303498B1 (no) 1998-07-20
KR0137959B1 (ko) 1998-05-15
FI103668B (fi) 1999-08-13
AU632288B2 (en) 1992-12-24
FI103668B1 (fi) 1999-08-13
GR3035589T3 (en) 2001-06-29
DE68929275T2 (de) 2001-05-23
DK41791D0 (da) 1991-03-08
US5541339A (en) 1996-07-30
DK175458B1 (da) 2004-11-01
JPH04500664A (ja) 1992-02-06
ATE198335T1 (de) 2001-01-15
AU4192289A (en) 1990-04-02
NO910958L (no) 1991-05-10

Similar Documents

Publication Publication Date Title
KR900701801A (ko) 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
MXPA04003564A (es) Bases de nitrogeno fotoactivables.
ES2175919T3 (es) Derivados del camptothecin con actividad antitumoral.
GB9505025D0 (en) Chemical compounds
DE69108665D1 (de) Tricyclische Heteroringe.
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.
DK554288A (da) Heterocycliske spiro-forbindelser og fremgangsmaade til fremstilling deraf
DE69132687D1 (de) Pestizide 1-Arylimidazole
ECSP055614A (es) Compuestos quimicos
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5560538A2 (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina
CO5570675A2 (es) Compuestos sustituidos de benzimidazolo y su uso para el tratamiento del cancer
EP0359454A1 (en) Novel CC-1065 analogs having two CPI subunits
AR046041A1 (es) Procedimiento para la preparacion de compuestos heterociclicos n-amino sustituidos
EA200001165A1 (ru) Производные тетрагидрохинолина в качестве антагонистов глицина
EA200500718A1 (ru) Замещённые 6-(2-галогенфенил)триазолопиримидины
AR049654A1 (es) Derivados de tetrahidroquinolina como reguladores de proteinas motoras mitoticas
DE502004004498D1 (de) Unsymmetrische lineare organische Oligomere
ATE581T1 (de) M-anilidurethane und diese enthaltende herbizide.
Sprecker et al. Fluorescent cytokinins: Stretched-out analogs of N6-benzyladenine and N6-(Δ2-isopentenyl) adenine
FI843502L (fi) 6-sulfoxifenolderivat, deras framstaellning och deras anvaendning som cellskyddsaemnen.
FI860443A0 (fi) 5-sulfonamido-1-aryl-pyrazoler.
Matosiuk Synthesis of 1, 6-Diaryl-5, 7-dioxo (dithio) imidazo [1, 2-a][1, 3, 5] triazines. A Novel Pathway for Imidazo [1, 2-a][1, 3, 5] triazine Systems Obtained via 1-(Imidazolin-2-yl) urea and Thiourea Derivatives
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
Karaböcek et al. The effect of intramolecular‐hydrogen bonds in the synthesis of novel imidates from a 13‐membered dioxadithia crown ether diester

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20050630

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060214

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060214

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000